Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Opinion
  • Published:

The future of bladder cancer care in the USA

Nature Reviews Urology volume 11, pages 59–62 (2014)Cite this article

Subjects

Abstract

Bladder cancer is the fifth most common malignancy in the USA and the most expensive to treat on a per-patient basis. Despite its prevalence, morbidity, mortality and associated cost of management, bladder cancer remains grossly under-recognized as a public health concern and underfunded scientifically. Although 5-year survival rates for patients with prostate or kidney cancer have improved tremendously in the past 30 years, progress in bladder cancer has stalled. A renewed interest from the clinical and research communities, as well as a young and eager advocacy network, are raising the profile of bladder cancer. As awareness and funding of bladder cancer increase, improved diagnostics, therapeutics and health services for patients with the disease will develop accordingly.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Siegel, R., Ward, E. & Brawley, O. Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J. Clin. 61, 212–236 (2011).

    PubMed  Google Scholar 

  2. Siegel, R., Naishadham, D. & Jemal, A. Cancer statistics, 2012. CA Cancer J. Clin. 62, 10–29 (2012).

    PubMed  Google Scholar 

  3. Botteman, M. F. et al. The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics 21, 1315–1330 (2003).

    PubMed  Google Scholar 

  4. Lotan, Y. et al. Key concerns about the current state of bladder cancer: a position paper from the Bladder Cancer Think Tank, the Bladder Cancer Advocacy Network, and the Society of Urologic Oncology. Cancer 115, 4096–4103 (2009).

    Article  PubMed  Google Scholar 

  5. Soloway, M. S. Bladder carcinoma: where are the patient advocates? Cancer 8, 1559–1562 (2005).

    Article  Google Scholar 

  6. Williamson, J. M. L., Jones, I. H. & Hocken, D. B. How does the media profile of cancer compare with prevalence? Ann. R. Coll. Surg. Engl. 93, 9–12 (2011).

    Article  CAS  PubMed  Google Scholar 

  7. Bjurlin, M. A. et al. Ethnicity and smoking status are associated with awareness of smoking related genitourinary disease. J. Urol. 188, 724–728 (2012).

    Article  PubMed  Google Scholar 

  8. Hansen, R. P. et al. Time intervals from first symptom to treatment of cancer: a cohort study of 2,212 newly diagnosed cancer patients. BMC Health Serv. Res. 11, 284–291 (2011).

    Article  PubMed  PubMed Central  Google Scholar 

  9. Hollenbeck, D. K. et al. Delays in diagnosis and bladder cancer mortality. Cancer 116, 5235–5242 (2010).

    Article  PubMed  Google Scholar 

  10. Messing, E. M. et al. Long-term outcome of hematuria screening for bladder cancer in men. Cancer 107, 2173–2179 (2006).

    Article  PubMed  Google Scholar 

  11. Gore, J. L., Lai, J., Setodji, C. M., Litwin, M. S. & Saigal, C. S. Mortality increases when radical cystectomy is delayed more than 12 weeks: results from a Surveillance, Epidemiology, and End Results-Medicare analysis. Cancer 115, 988–996 (2009).

    Article  PubMed  Google Scholar 

  12. Bladder Cancer Advocacy Network [online], (2013).

  13. Carter, A. J. & Nguyen, C. N. A comparison of cancer burden and research spending reveals discrepancies in the distribution of research funding. BMC Public Health 12, 526–537 (2012).

    Article  PubMed  PubMed Central  Google Scholar 

  14. Bachir, B. G. et al. Demographic analysis of randomized controlled trials in bladder cancer. BJU Int. http://dx.doi.org/10.1111/j.1464-410X.2012.11401.x

  15. Soloway, M. S. Bladder cancer: Lack of progress in bladder cancer—what are the obstacles? Nat. Rev. Urol. 10, 5–6 (2012).

    Article  PubMed  Google Scholar 

  16. Chamie, K. et al. Compliance with guidelines for patients with bladder cancer: variations in the delivery of care. Cancer 117, 5392–5401 (2011).

    Article  PubMed  Google Scholar 

  17. Madeb, R. et al. Treatment of non-muscle invading bladder cancer: do physicians in the United States practice evidence based medicine? The use and economic implications of intravesical chemotherapy after transurethral resection of bladder tumors. Cancer 115, 2660–2670 (2009).

    Article  PubMed  Google Scholar 

  18. Lee, C. T. et al. Economic and humanistic consequences of preventable bladder tumor recurrences in nonmuscle invasive bladder cancer cases. J. Urol. 188, 2114–2119 (2012).

    Article  PubMed  Google Scholar 

  19. Herr, H. W. et al. Surgical factors influence bladder cancer outcomes: a cooperative group report. J. Clin. Oncol. 22, 2781–2789 (2004).

    Article  PubMed  Google Scholar 

  20. Steven, K. & Poulsen, A. L. Radical cystectomy and extended pelvic lymphadenectomy: survival of patients with lymph node metastasis above the bifurcation of the common iliac vessels treated with surgery only. J. Urol. 178, 1218–1223 (2007).

    Article  PubMed  Google Scholar 

  21. SWOG. SWOG S1011 Bladder Cancer Trial: patient information [online], (2013).

  22. Spencer, B. A. et al. Quality-of-care indicators for early-stage prostate cancer. J. Clin. Oncol. 21, 1928–1936 (2003).

    Article  PubMed  Google Scholar 

  23. Cooperberg, M. R., Porter, M. P. & Konety, B. R. Candidate quality of care indicators for localized bladder cancer. Urol. Oncol. 27, 435–442 (2009).

    Article  PubMed  Google Scholar 

  24. Sutton, M. et al. Reduced hospital mortality with hospital pay for performance in England. N. Engl. J. Med. 367, 1821–1828 (2012).

    Article  CAS  PubMed  Google Scholar 

  25. Epstein, A. M. Will pay for performance improve quality of care? The answer is in the details. N. Engl. J. Med. 367, 1852–1853 (2012).

    Article  CAS  PubMed  Google Scholar 

  26. Gonzalgo, M. L., Schoenberg, M. P. & Rodriguez, R. Biological pathways to bladder carcinogenesis. Semin. Urol. Oncol. 18, 256–263 (2000).

    CAS  PubMed  Google Scholar 

  27. Adams, R. M. Databases and the future of clinical trials in bladder cancer. Urol. Oncol. 25, 330–332 (2007).

    Article  PubMed  Google Scholar 

  28. Chang, S. S. et al. 12th Annual meeting of the Society of Urologic Oncology (SUO) bladder cancer sessions I and II summary report. Urol. Oncol. 30, 944–947 (2012).

    Article  PubMed  Google Scholar 

  29. Svatek, R. S. et al. Summary of the 6th annual bladder cancer think tank: New directions in urologic research. Urol. Oncol. http://dx.doi.org/10.1016/j.urolonc.2011.12.017.

  30. Lerner, S. P. Bladder cancer clinical trials. Urol. Oncol. 23, 275–279 (2005).

    Article  PubMed  Google Scholar 

  31. National Cancer Institute. Clinical Trials [online], (2013).

  32. Mallin, K., David, K. A., Carroll, P. R., Milowsky, M. I. & Nanus, D. M. Transitional cell carcinoma of the bladder: Racial and gender disparities in survival (1993 to 2002), stage and grade (1993 to 2007). J. Urol. 185, 1631–1636 (2011).

    Article  PubMed  Google Scholar 

  33. Grossman, H. B. et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N. Engl. J. Med. 349, 859–866 (2003).

    CAS  PubMed  Google Scholar 

  34. Fedeli, U., Fedewa, S. A. & Ward, E. M. Treatment of muscle invasive bladder cancer: evidence from the National Cancer Database, 2003 to 2007. J. Urol. 185, 72–78 (2011).

    Article  PubMed  Google Scholar 

  35. International Collaboration of Trialists et al. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J. Clin. Oncol. 29, 2171–2177 (2011).

  36. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Adjuvant chemotherapy for invasive bladder cancer (individual patient data). Cochrane Database Syst. Rev. CD006018 (2006).

  37. Konety, B. R., Joyce, G. F. & Wise, M. Bladder and upper tract urothelial cancer. J. Urol. 177, 1636–1645 (2007).

    Article  PubMed  Google Scholar 

  38. Keegan, K. A. et al. Changing utilization of neoadjuvant and adjuvant chemotherapies for muscle-invasive urothelial carcinoma after publication of landmark manuscripts [abstract 527]. 187, e216–e217 (2012).

  39. Alva, A. S. et al. Efficient delivery of radical cystectomy after neoadjuvant chemotherapy for muscle-invasive bladder cancer: a multidisciplinary approach. Cancer 188, 44–53 (2012).

    Article  Google Scholar 

  40. Kurpad, R. et al. A multidisciplinary approach to the management of urologic malignancies: does it influence diagnostic and treatment decisions? Urol. Oncol. 29, 378–382 (2011).

    Article  PubMed  Google Scholar 

  41. Apolo, A. B., Grossman, H. B., Bajorin, D., Steinberg, G. & Kamat, A. M. Practical use of perioperative chemotherapy for muscle-invasive bladder cancer: summary of session at the Society for Urologic Oncology annual meeting. Urol. Oncol. 30, 772–780 (2012).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Howlander, N. et al. SEER Cancer Statistics Review: 1975–2009. Surveillance Epidemiology and End Results [online], (2013).

    Google Scholar 

  43. Ko, C. & Chaudhry, S. The need for a multidisciplinary approach to cancer care. J. Surg. Res. 105, 53–57 (2002).

    Article  PubMed  Google Scholar 

  44. Bassett, J. C. et al. Impact of a bladder cancer diagnosis on smoking behavior. J. Clin. Oncol. 30, 1871–1878 (2012).

    Article  PubMed  Google Scholar 

  45. Pawlson, L. G. et al. Patient-centered medical home from vision to reality. California Department of Health Care Services [online], (2013).

    Google Scholar 

  46. Sia, C., Tonniges, T. F., Osterhus, E. & Taba, S. History of the medical home concept. Pediatrics 113, 1473–1478 (2004).

    PubMed  Google Scholar 

  47. Peikes, D. et al. Early evidence on the Patient-Centered Medical Home. Agency for Healthcare Research and Quality [online], (2013).

    Google Scholar 

  48. Wender, R. C. & Altshuler, M. Can the medical home reduce cancer morbidity and mortality? Prim. Care 36, 845–858, (2009).

    Article  PubMed  Google Scholar 

  49. Chamie, K. et al. Quality of care in patients with bladder cancer: a case report? Cancer 118, 1412–1421 (2012).

    Article  PubMed  Google Scholar 

  50. Sprandio, J. D. Oncology patient-centered medical home and accountable cancer care. Commun. Oncol. 7, 565–572 (2010).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Health Services Research Group, David Geffen School of Medicine at UCLA, 924 Westwood Boulevard, Suite 1000, Los Angeles, 90024, CA, USA

    Alan L. Kaplan, Mark S. Litwin & Karim Chamie

Authors
  1. Alan L. Kaplan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mark S. Litwin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Karim Chamie
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

A. L. Kaplan and K. Chamie researched data for the article, contributed to the discussion of content and wrote the article. All authors reviewed the manuscript before submission.

Corresponding author

Correspondence to Karim Chamie.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kaplan, A., Litwin, M. & Chamie, K. The future of bladder cancer care in the USA. Nat Rev Urol 11, 59–62 (2014). https://doi.org/10.1038/nrurol.2013.180

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrurol.2013.180

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing